Akebia Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Akebia Therapeutics Inc reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of six analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -6 cents to -2 cents per share.

• Revenue fell 37.2% to $36.90 million from a year ago; analysts expected $46.94 million.

• Akebia Therapeutics Inc's reported EPS for the quarter was a loss of 5 cents​.

• The company reported a quarterly loss of $14.35 million.

• Akebia Therapeutics Inc shares had fallen by 24.5% this quarter and lost 56.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Akebia Therapeutics Inc is $4.00, about 82.6% above its last closing price of $0.69

This summary was machine generated from LSEG data November 5 at 04:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)